Yamanaka Ryuya, Homma Junpei, Yajima Naoki, Tsuchiya Naoto, Tanaka Ryuichi
Department of Neurosurgery, Brain Research Institute, Niigata University, 1-757 Asahimachi-dori, Niigata 951-8585, Japan.
No To Shinkei. 2003 Sep;55(9):771-80.
Despite advances in radiation and chemotherapy along with surgical resectioning, the prognosis of patients with malignant glioma is poor. Among the new treatments currently being investigated for malignant glioma, immunotherapy is theoretically very attractive, since it offers the potential for high tumor-specific cytotoxicity. There are increasing reports demonstrating that systemic immunotherapy using dendritic cells is capable of inducing an antiglioma response. Therefore, dendritic cell-based immunotherapy could be a new treatment modality for patients with glioma. Dendritic cell-based immunotherapy strategies appear promising as an approach to successfully induce an antitumor immune response and increase survival in patients with glioma. The development of methods for manipulating dendritic cells for the purpose of vaccination will enhance the clinical usefulness of these cells for biotherapy for malignant glioma.
尽管在放射治疗、化学治疗以及手术切除方面取得了进展，但恶性胶质瘤患者的预后仍然很差。在目前针对恶性胶质瘤正在研究的新治疗方法中，免疫疗法在理论上非常具有吸引力，因为它具有产生高度肿瘤特异性细胞毒性的潜力。越来越多的报告表明，使用树突状细胞的全身免疫疗法能够诱导抗胶质瘤反应。因此，基于树突状细胞的免疫疗法可能成为胶质瘤患者的一种新的治疗方式。基于树突状细胞的免疫治疗策略作为一种成功诱导抗肿瘤免疫反应并提高胶质瘤患者生存率的方法，似乎很有前景。为了疫苗接种目的而操纵树突状细胞的方法的开发将提高这些细胞在恶性胶质瘤生物治疗中的临床实用性。
No To Shinkei. 2003-9
Int J Oncol. 2003-7
Brain Nerve. 2007-3
Curr Opin Mol Ther. 2006-2
Adv Exp Med Biol. 2012
Trends Mol Med. 2008-5
Expert Rev Neurother. 2005-7
Neurosurg Rev. 2009-7
Zotero 插件